Proapoptotic effects of the novel proteasome inhibitor b-AP15 on multiple myeloma cells and natural killer cells

Experimental Hematology

Volumn 42, Issue 3, 2014, Pages 172-182

  Feng, Xiaoli ^a   Holmlund, Teresa ^a   Zheng, Chengyun ^b,c   Fadeel, Bengt ^a,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b SHANDONG UNIVERSITY   (China)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B AP15; BETA ACTIN; BORTEZOMIB; CASPASE 3; CATHEPSIN D; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PHOSPHATIDYLSERINE; PROTEIN BAX; UBIQUITIN; UNCLASSIFIED DRUG;

ADULT; AMINO TERMINAL SEQUENCE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; MULTIPLE MYELOMA; MYELOMA CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN CONFORMATION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; UBIQUITINATION;

ADULT; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CASPASE 3; CATHEPSIN D; CELL LINE, TUMOR; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMANS; KILLER CELLS, NATURAL; MEMBRANE POTENTIAL, MITOCHONDRIAL; MITOCHONDRIA; MULTIPLE MYELOMA; PHOSPHATIDYLSERINES; PIPERIDONES; POLY(ADP-RIBOSE) POLYMERASES; PROTEASE INHIBITORS; TIME FACTORS;

EID: 84897801794     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2013.11.010     Document Type: Article

References (42)

1. Suzuki K. Current therapeutic strategy for multiple myeloma. Jpn J Clin Oncol 2013, 43:116-124.
2. Dolloff N., Talamo G. Targeted therapy of multiple myeloma. Adv Exp Med Biol 2013, 779:197-221.
3. Richardson P., Anderson K. Bortezomib: a novel therapy approved for multiple myeloma. Clin Adv Hematol Oncol 2003, 1:596-600.
4. Richardson P., Barlogie B., Berenson J., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003, 348:2609-2617.
5. Kuhn D., Chen Q., Voorhees P., et al. Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma. Blood 2007, 110:3281-3290.
6. Parlati F., Lee S., Aujay M., et al. Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome. Blood 2009, 114:3439-3447.
7. Zhou H.-J., Aujay M., Bennett M., et al. Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). J Med Chem 2009, 52:3028-3038.
8. Erdal H., Berndtsson M., Castro J., Brunk U., Shoshan M., Linder S. Induction of lysosomal membrane permeabilization by compounds that activate p53-independent apoptosis. Proc Natl Acad Sci U S A 2005, 102:192-197.
9. D'Arcy P., Brnjic S., Olofsson M., et al. Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nat Med 2011, 17:1636-1640.
10. D'Arcy P., Linder S. Proteasome deubiquitinases as novel targets for cancer therapy. Int J Biochem Cell Biol 2012, 44:1729-1738.
11. Ling X., Calinski D., Chanan-Khan A., Zhou M., Li F. Cancer cell sensitivity to bortezomib is associated with survivin expression and p53 status but not cancer cell types. J Exp Clin Cancer Res 2010, 29:8.
12. Paoluzzi L., Gonen M., Bhagat G., et al. The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood 2008, 112:2906-2916.
13. Caligiuri M. Human natural killer cells. Blood 2008, 112:461-469.
14. Smyth M., Cretney E., Kelly J., et al. Activation of NK cell cytotoxicity. Mol Immunol 2005, 42:501-510.
15. Falschlehner C., Schaefer U., Walczak H. Following TRAIL's path in the immune system. Immunology 2009, 127:145-154.
16. Suliman A., Lam A., Datta R., Srivastava R. Intracellular mechanisms of TRAIL: apoptosis through mitochondrial-dependent and -independent pathways. Oncogene 2001, 20:2122-2133.
17. Wilson N., Dixit V., Ashkenazi A. Death receptor signal transducers: nodes of coordination in immune signaling networks. Nat Immunol 2009, 10:348-355.
18. Kim S., Kim K., Kim B., et al. Bortezomib and the increased incidence of herpes zoster in patients with multiple myeloma. Clin Lymphoma Myeloma 2008, 8:237-240.
19. Wang X., Ottosson A., Ji C., et al. Proteasome inhibition induces apoptosis in primary human natural killer cells and suppresses NKp46-mediated cytotoxicity. Haematologica 2009, 94:470-478.
20. Feng X., Yan J., Wang Y., et al. The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells. Mol Immunol 2010, 47:2388-2396.
21. Sun Y., Ottosson A., Pervaiz S., Fadeel B. Smac-mediated sensitization of human B-lymphoma cells to staurosporine- and lactacystin-triggered apoptosis is apoptosome-dependent. Leukemia 2007, 21:1035-1043.
22. Ottosson-Wadlund A., Ceder R., Preta G., et al. Requirement of apoptotic protease-activating factor-1 for bortezomib-induced apoptosis but not for Fas-mediated apoptosis in human leukemic cells. Mol Pharmacol 2013, 83:245-255.
23. Andón F., Fadeel B. Programmed cell death: molecular mechanisms and implications for safety assessment of nanomaterials. Acc Chem Res 2013, 46:733-742.
24. Berndtsson M., Beaujouin M., Rickardson L., et al. Induction of the lysosomal apoptosis pathway by inhibitors of the ubiquitin-proteasome system. Int J Cancer 2009, 15:1463-1469.
25. Fadeel B., Ottosson A., Pervaiz S. Big wheel keeps on turning: apoptosome regulation and its role in chemoresistance. Cell Death Differ 2008, 15:443-452.
26. Laane E., Panaretakis T., Pokrovskaja K., et al. Dexamethasone-induced apoptosis in acute lymphoblastic leukemia involves differential regulation of Bcl-2 family members. Haematologica 2007, 92:1460-1469.
27. Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell 1994, 79:13-21.
28. Ciechanover A. The ubiquitin-proteasome pathway: on protein death and cell life. The EMBO J 1998, 17:7151-7160.
29. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004, 4:349-360.
30. Moreau P., Richardson P., Cavo M., et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood 2012, 120:947-959.
31. Goldberg A. Development of proteasome inhibitors as research tools and cancer drugs. J Cell Biol 2012, 199:583-588.
32. Buac D., Shen M., Schmitt S., et al. From bortezomib to other inhibitors of the proteasome and beyond. Curr Pharm Des 2013, 19:4025-4038.
33. Daviet L., Colland F. Targeting ubiquitin specific proteases for drug discovery. Biochimie 2008, 90:270-283.
34. Chandler J., Cohen G., MacFarlane M. Different subcellular distribution of caspase-3 and caspase-7 following Fas-induced apoptosis in mouse liver. J Biol Chem 1998, 1:10815-10818.
35. Turk B., Stoka V. Protease signalling in cell death: caspases versus cysteine cathepsins. FEBS Lett 2007, 19:2761-2767.
36. Conus S., Pop C., Snipas S., et al. Cathepsin D primes caspase-8 activation by multiple intra-chain proteolysis. J Biol Chem 2012, 15:21142-21151.
37. Brnjic S., Mazurkiewicz M., Fryknäs M., et al. Induction of tumor cell apoptosis by a proteasome deubiquitinase inhibitor is associated with oxidative stress. Antioxid Redox Signal 2013, [Epub ahead of print].
38. Davenport E., Moore H., Dunlop A., et al. Heat shock protein inhibition is associated with activation of the unfolded protein response pathway in myeloma plasma cells. Blood 2007, 1:2641-2649.
39. Berges C., Haberstock H., Fuchs D., et al. Proteasome inhibition suppresses essential immune functions of human CD4+ T cells. Immunology 2008, 124:234-246.
40. Straube C., Wehner R., Wendisch M., et al. Bortezomib significantly impairs the immunostimulatory capacity of human myeloid blood dendritic cells. Leukemia 2007, 21:1464-1471.
41. Blanco B., Pérez-Simón J., Sánchez-Abarca L., et al. Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines. Blood 2006, 107:3575-3583.
42. Basler M., Lauer C., Beck U., Groettrup M. The proteasome inhibitor bortezomib enhances the susceptibility to viral infection. J Immunol 2009, 183:6145-6150.